Analysis of blood biomarkers in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The ALCINA 4 study is a prospective biological cohort study that focuses on analyzing circulating tumor biomarkers obtained through blood sampling from cancer patients. Participants will provide up to four blood samples over a period of 12 to 18 months, with the timing varying based on the specific cohort and clinical context. The study aims to explore various biomarkers, including circulating tumor cells and circulating tumor DNA, to enhance cancer diagnosis, prognosis, and treatment efficacy. Additionally, it may involve tumor biopsies if necessary for comparison with blood samples.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient treated for cancer at one of the participating center
* 18 years old or higher
* Signed informed consent form
* Patient not deprived of their liberty or under guardianship (including temporary guardianship)
* Patient covered by social security scheme
* Patient with no compliance issue (related to geographical, social or psychological reasons) for study follow up
* Other additional criteria will be defined (defining tumor type and clinical setting), by cohort

If a biopsy tumor sample is to be taken:

* Tumor considered as accessible by biopsy (at the investigator's discretion).
* Normal blood coagulation tests (if applicable, and in case of a non-superficial tumor lesion).
* No anticoagulant or antiaggregant treatment for the biopsy.

Exclusion Criteria :

Pregnant and/or breast-feeding women depending on cohort.

Where it's running

• Institut Curie
  Paris, France Recruiting
• Institut Curie
  Saint-Cloud, France Recruiting

Study contacts

• Principal investigator: Francois-Clement BIDARD — Institut Curie
• Study coordinator: Marie-Emmanuelle LEGRIER
• Email: drci.promotion@curie.fr
• Phone: 0033156245649

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Compare a new endoscopy-assisted breast-conserving surgery with the usual approach

  This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang and 21 other locations · NCT07920094

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.